Compare Recursion Pharmaceuticals Inc (RXRX) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs ABRDN Physical Gold Shares ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B), while ABRDN Physical Gold Shares ETF trades at $39.92 (market cap $7.03B). The key difference: ABRDN Physical Gold Shares ETF is far larger — about 3.3× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, ABRDN Physical Gold Shares ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and ABRDN Physical Gold Shares ETF for 57 Days on average.
| RXRX | SGOL | |
|---|---|---|
Market Cap | $2.14B | $7.03B |
Volume | 30,789,535 | 2,350,550 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $6.79 | $51.41 |
52-Week Low | $2.84 | $37.54 |
Typical Hold Time | 22 Days | 57 Days |
Enterprise Value | $1.66B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
SGOL is trading at $39.02, down 1.66% with bearish technical signals dominating across moving averages and oscillators. The stock faces significant resistance at current levels with all support and resistance clustered around $39. Recent market sentiment reflects pressure from rising Treasury yields and Federal Reserve policy uncertainty, though some technical indicators like the 12-day RSI at 24.81 suggest potential oversold conditions.
The outlook remains challenging with persistent bearish momentum, though the deeply oversold RSI reading indicates potential for near-term stabilization. Investment opportunities exist for contrarian investors seeking gold exposure amid inflation concerns, while risks include continued pressure from rising interest rates and dollar strength that could push prices lower.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
